The first patient has been dosed in a clinical trial assessing immuno-PET developer ImaginAb's PET/CT imaging agent CD8 ImmunoPET (zirconium-89 [Zr-89] crefmirlimab berdoxam).
The agent was used for the first time at the Macquarie University Hospital in Sydney, Australia, with a patient enrolled in the Individualized Therapy for Advanced or Poor Prognosis Cancers (I-PREDICT). The trial is being conducted at sites in the U.S., Australia, and Europe.
The trial is assessing the performance of CD8 ImmunoPET PET/CT for predicting patient response to immuno-oncology therapy that targets melanoma, Merkel and renal cell carcinoma, and non-small cell lung cancer, according to ImaginAb.
